KAZAN, Russian Federation,
March 30 /PRNewswire-FirstCall/ -
Neuro-Biotech Corp. (PINKSHEETS: MRES) MRES is pleased to announce
the resumption of the buyout offer at $0.15 by AURIC Pharma Science.
Following a letter received over the weekend by AURIC,
Neuro-Biotech management has decided that it was in both the
Company's and shareholders best interest to proceed with the buyout
offer. Therefore, the Company would like to announce the completion
of its due diligence process and that it will proceed to the
closing session of this transaction by Tuesday April 5, 2011. The Company will be
announcing the exact time and place of the closing session on
Thursday March 31, 2011. Shareholders
that would like to participate are invited to register with the
Company at: contact@neuro-biotechcorp.com.
Forward Looking Statements
This release contains statements that are made pursuant to the
Safe Harbor Provisions of the Private Securities Litigation Act of
1995. Certain statements in this press release may contain words
such as "anticipates," "believes," "could," "expects," "intends,"
"may," "projects," "targets" and other similar language that is
considered forward-looking statements. These forward-looking
statements are subject to certain risks and uncertainties and
persons reading this release are cautioned that such statements are
only predictions, and that the Company's actual future results or
performance may be materially different. The Company disclaims any
intention or obligation to update or revise forward-looking
information, whether as a result of new information, future events,
or otherwise, could cause the company's actual results to differ
materially from those indicated in any forward-looking
statements.
SOURCE Neuro-Biotech Corp.